skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions

Abstract

Receptor protein tyrosine kinases (RPTKs) are essential mediators of cell growth, differentiation, migration, and metabolism. Recently, a novel RPTK named NOK has been cloned and characterized. In current study, we investigated the role of the carboxyl terminal tyrosine 417 residue of NOK in the activations of different signaling pathways. A single tyrosine to phenylalanine point mutation at Y417 site (Y417 F) not only dramatically enhanced the NOK-induced activation of extracellular signal-regulated kinase (ERK), but also markedly promoted the NOK-mediated activation of both signal transducer and activator of transcription 1 and 3 (STAT1 and 3). Moreover, the proliferation potential of NIH3T3-NOK (Y417F) stable cells were significantly elevated as compared with that of NIH3T3-NOK. Overall, our results demonstrate that the tyrosine Y417 residue at the carboxyl tail of NOK exhibits an autoinhibitory role in NOK-mediated signaling transductions.

Authors:
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [2]
  1. Tsinghua Institute of Genome Research, Institute of Biomedicine and School of Medicine, Tsinghua University, Beijing 100084 (China)
  2. Tsinghua Institute of Genome Research, Institute of Biomedicine and School of Medicine, Tsinghua University, Beijing 100084 (China) and Department of Microbiology and Etiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005 (China). E-mail: Liu_Li@mail.tsinghua.edu.cn
Publication Date:
OSTI Identifier:
20991323
Resource Type:
Journal Article
Resource Relation:
Journal Name: Biochemical and Biophysical Research Communications; Journal Volume: 356; Journal Issue: 2; Other Information: DOI: 10.1016/j.bbrc.2007.02.154; PII: S0006-291X(07)00455-X; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; CELL PROLIFERATION; GENE MUTATIONS; METABOLISM; NITRIC OXIDE; PHENYLALANINE; PHOSPHOTRANSFERASES; RECEPTORS; TRANSCRIPTION; TYROSINE

Citation Formats

Li Yinghua, Zhong Shan, Rong Zhili, Ren Yongming, Li Zhiyong, Zhang Shuping, Chang Zhijie, and Liu Li. The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions. United States: N. p., 2007. Web.
Li Yinghua, Zhong Shan, Rong Zhili, Ren Yongming, Li Zhiyong, Zhang Shuping, Chang Zhijie, & Liu Li. The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions. United States.
Li Yinghua, Zhong Shan, Rong Zhili, Ren Yongming, Li Zhiyong, Zhang Shuping, Chang Zhijie, and Liu Li. Fri . "The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions". United States. doi:.
@article{osti_20991323,
title = {The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions},
author = {Li Yinghua and Zhong Shan and Rong Zhili and Ren Yongming and Li Zhiyong and Zhang Shuping and Chang Zhijie and Liu Li},
abstractNote = {Receptor protein tyrosine kinases (RPTKs) are essential mediators of cell growth, differentiation, migration, and metabolism. Recently, a novel RPTK named NOK has been cloned and characterized. In current study, we investigated the role of the carboxyl terminal tyrosine 417 residue of NOK in the activations of different signaling pathways. A single tyrosine to phenylalanine point mutation at Y417 site (Y417 F) not only dramatically enhanced the NOK-induced activation of extracellular signal-regulated kinase (ERK), but also markedly promoted the NOK-mediated activation of both signal transducer and activator of transcription 1 and 3 (STAT1 and 3). Moreover, the proliferation potential of NIH3T3-NOK (Y417F) stable cells were significantly elevated as compared with that of NIH3T3-NOK. Overall, our results demonstrate that the tyrosine Y417 residue at the carboxyl tail of NOK exhibits an autoinhibitory role in NOK-mediated signaling transductions.},
doi = {},
journal = {Biochemical and Biophysical Research Communications},
number = 2,
volume = 356,
place = {United States},
year = {Fri May 04 00:00:00 EDT 2007},
month = {Fri May 04 00:00:00 EDT 2007}
}
  • Digestion of human ..cap alpha../sub 2/-macroglobulin-methylamine with papain prior to gel filtration resulted in the resolution of three distinct peaks. The material in peak I and peak II did not have any receptor binding ability as determined by in vivo clearance studies and in vitro competitive binding studies using mouse peritoneal macrophages. In contrast, the material in peak III bound to macrophage ..cap alpha../sub 2/-macroglobulin receptors with a K/sub d/ of 250 nM. This represents a 500-fold decrease in affinity relative to undigested ..cap alpha../sub 2/M-CH/sub 3/NH/sub 2/. Sequence analysis demonstrated that this material constituted the carboxyl-terminal fragment (COOH-terminal fragment)more » of ..cap alpha../sub 2/M. ..cap alpha../sub 2/M is known to possess a methionyl residue which is susceptible to modification by cis-dichlorodiammineplatinum (II) (cis-DDP) with the result being a loss of receptor binding ability by ..cap alpha../sub 2/M. For this reason, experiments were performed to determine if the platinum-reactive methionyl residue is located in the COOH-terminal receptor binding fragment of ..cap alpha../sub 2/M. The results of this investigation demonstrate that cis-DDP is not reactive with either the isolated COOH-terminal fragment or the COOH-terminal fragment isolated from ..cap alpha../sub 2/M-CH/sub 3/NH/sub 2/ which had been pretreated with cis-DDP. In addition, the COOH-terminal fragment did not bind to monoclonal antibody 7H11D6, a monoclonal antibody which binds to the platinum-reactive epitope of the ..cap alpha../sub 2/M-CH/sub 3/NH/sub 2/ receptor recognition site. The results of this investigation demonstrate that this fragment is not the complete receptor recognition site and suggest that a platinum-reactive methionyl residue located in the 55-kDa fragment of ..cap alpha../sub 2/M is another component of this site.« less
  • Deubiquitinating enzymes (DUBs) appear to be critical regulators of a multitude of processes such as proliferation, apoptosis, differentiation, and inflammation. We have recently demonstrated that a DUB of ubiquitin carboxyl terminal hydrolase L1 (UCH-L1) inhibits vascular lesion formation via suppressing inflammatory responses in vasculature. However, the precise underlying mechanism remains to be defined. Herein, we report that a posttranscriptional up-regulation of UCH-L1 provides a negative feedback to tumor necrosis factor alpha (TNF{alpha})-mediated activation of extracellular signal-regulated kinases (ERK) and proliferation in vascular smooth muscle cells (VSMCs). In rat adult VSMCs, adenoviral over-expression of UCH-L1 inhibited TNF{alpha}-induced activation of ERK andmore » DNA synthesis. In contrast, over-expression of UCH-L1 did not affect platelet derived growth factor (PDGF)-induced VSMC proliferation and activation of growth stimulating cascades including ERK. TNF{alpha} hardly altered UCH-L1 mRNA expression and stability; however, up-regulated UCH-L1 protein expression via increasing UCH-L1 translation. These results uncover a novel mechanism by which UCH-L1 suppresses vascular inflammation.« less
  • {delta}-Opioid receptor (DOR) agonists possess cytoprotective properties, an effect associated with activation of the 'pro-survival' kinase Akt. Here we delineate the signal transduction pathway by which opioids induce Akt activation in neuroblastoma x glioma (NG108-15) hybrid cells. Exposure of the cells to both [D-Pen{sup 2,5}]enkephalin and etorphine resulted in a time- and dose-dependent increase in Akt activity, as measured by means of an activation-specific antibody recognizing phosphoserine-473. DOR-mediated Akt signaling is blocked by the opioid antagonist naloxone and involves inhibitory G{sub i/o} proteins, because pre-treatment with pertussis toxin, but not over-expression of the G{sub q/11} scavengers EBP50 and GRK2-K220R, preventedmore » this effect. Further studies with Wortmannin and LY294002 revealed that phophoinositol-3-kinase (PI3K) plays a central role in opioid-induced Akt activation. Opioids stimulate Akt activity through transactivation of receptor tyrosine kinases (RTK), because pre-treatment of the cells with inhibitors for neurotrophin receptor tyrosine kinases (AG879) and the insulin-like growth factor receptor IGF-1 (AG1024), but not over-expression of the G{beta}{gamma} scavenger phosducin, abolished this effect. Activated Akt translocates to the nuclear membrane, where it promotes GSK3 phosphorylation and prevents caspase-3 cleavage, two key events mediating inhibition of cell apoptosis and enhancement of cell survival. Taken together, these results demonstrate that in NG108-15 hybrid cells DOR agonists possess cytoprotective properties mediated by activation of the RTK/PI3K/Akt signaling pathway.« less
  • Ligation of cancer cell surface GRP78 by activated {alpha}{sub 2}-macroglobulin ({alpha}{sub 2}M{sup *}) triggers pro-proliferative and anti-apoptotic signaling pathways. Cancer patients who develop autoantibodies to the {alpha}{sub 2}M{sup *} binding site in GRP78 have a poor prognosis since these antibodies are receptor agonists. The NF-{kappa}B family of transcription factors induces expression of genes affecting cell growth and differentiation. NF-{kappa}B1 plays a major regulatory role in controlling innate immunity and inflammation, whereas NF-{kappa}B2 plays a greater role in cancer cell proliferation. Here we report that treatment of prostate cancer cells with antibody directed against the carboxyl terminal domain of GRP78 inhibitsmore » {alpha}{sub 2}M{sup *}-induced activation of NF-{kappa}B2 by {approx}50% while exerting a lesser effect of {approx}20% on NF-{kappa}B1 activation. Treatment of these cells nearly abolished {alpha}{sub 2}M{sup *}-induced activation of IKK{alpha} involved in the activation of NF-{kappa}B2. This antibody also suppressed {alpha}{sub 2}M{sup *}-induced phosphorylation of IKK{alpha}, IKK{alpha}/{beta}, I{kappa}B{alpha}, and I{kappa}B{beta} as well as levels of NIK. Antibody treatment of cancer cells elevated pro-apoptotic p21WAF and p27kip while reducing cyclin D1 levels. These studies demonstrate that antibody directed against the carboxyl terminal domain of GRP78 inhibits the pro-proliferative NF-{kappa}B signaling cascade in cancer cells.« less